tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Steven Lichtman, 144 are a BUY (90%), 16 are a HOLD (10%).
Analyst Steven Lichtman, currently employed at WILLIAM BLAIR, carries an average stock price target met ratio of 66.07% that have a potential upside of 31.46% achieved within 269 days. Previously, Steven Lichtman worked at OPPENHEIMER.
Steven Lichtman’s has documented 340 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TNDM, Tandem Diabetes Care at 21-Aug-2026.
Analyst best performing recommendations are on CFMS (CONFORMIS).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 2/27/2019. The price target of $68 was fulfilled within 2 days with a profit of $6.14 (9.93%) receiving and performance score of 49.63.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 06-Feb-2020
$56
$11.04 (24.56%)
$60
Buy Since 06-Dec-2013
$56
$11.04 (24.56%)
$56
17 days ago
(25-Aug-2026)
24/36 (66.67%)
$6.14 (12.31%)
329
Buy Since 03-Apr-2024
$95
1 months 11 days ago
(31-Jul-2026)
2/2 (100%)
$19.83 (26.38%)
187
Buy Since 25-Apr-2019
$61
$16.04 (35.68%)
$70
1 months 12 days ago
(30-Jul-2026)
20/27 (74.07%)
$15 (32.61%)
274
Buy Since 30-May-2023
$67
$22.04 (49.02%)
$74
1 months 12 days ago
(30-Jul-2026)
5/11 (45.45%)
$21 (45.65%)
130
Which stock is Steven Lichtman most bullish on?
Which stock is Steven Lichtman most reserved on?
What Year was the first public recommendation made by Steven Lichtman?
